Exchange: NASDAQ·Updated 04:10 PM EST

COAG Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 10

Estimated EPS

-$0.50

Reported EPS

-$0.58

Surprise

-15.55%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

• Reported GAAP EPS of -$0.58 up 96.78% YoY • As of September 30, 2026, Hemab Therapeutics had $430.2M in cash, cash equivalents, and marketable securities and believes those resources will fund operating expenses and capital expenditure requirements into 2029.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.57
--
--
N/A
Q3 '26
-$0.50
-$0.58
-15.55%
MISSED
Q2 '26
-$0.73
-$0.80
-9.22%
MISSED
Q1 '26
-$23.25
--
--
N/A

Advertisement|Remove ads.